Replies to post #26961 on $heff's $tation of $tocks & $olid DD

[$heff]

POZN (10.86).. Senior Biotech Analyst thoughts on POZN earnings (due Apr 29th) and how his colleagues might have to raise their estimates due to Treximet in that it is no longer a flat-selling drug. Royalties also increased this year for Pozen from 5% to 18%.
http://finance.yahoo.com/news/Arthritis-Drug-Vimovo-twst-3473823072.html?x=0&.v=1
Dr. Jonathan Aschoff, Ph.D., is a Senior Equity Analyst at Brean Murray, Carret & Co., LLC

[naturallyk2]

This strongly suggests an even larger jump on share price on the day of approval of Vimovo. Definitely more than one catalyst with this company.